- Alnylam's stock is down 30% despite a booming biotech market. Here's why.Alnylam is one of biopharma’s biggest mysteries so far in 2026. The broader market is seeing a resurgence after years of a bearish environment. M&A is up, IPOs are back with record-breaking for…Endpoints · 48m ago↗ source
- Mirae raises $5.4M to turn patient texts into data for doctorsAs people increasingly turn to AI chatbots for health questions, one startup wants patients to talk to its chatbot about their symptoms, so their doctors can make better treatment decisions. Mira…Endpoints · 1h ago↗ source
- Claris collects $118M to take eye drop into pivotal testing next yearClaris Bio has a fresh CEO, new board chair and $118 million for two pivotal trials to see if its eye drop can succeed in a blinding disease with no pharmaceutical treatment options. It's a ...